SOSV

Oxyle specializes in wastewater treatment, focusing on the removal of hazardous micropollutants such as pesticides, chemicals, pharmaceuticals, and endocrine disruptors. Serving industries like pharmaceuticals, biotech, chemicals, food & beverage, electronics, hospitals, and wastewater plants, Oxyle's innovative technology helps reduce toxic pollutants and carbon emissions while providing regulatory relief to clients.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio is a biotechnology company focused on producing recombinant proteins. It specializes in creating advanced soluble ingredients with improved attributes such as enhanced gel and film formation, and antioxidant properties. The company's core expertise lies in developing non-immunogenic natural motifs to deliver functionalities for research, beauty, and healthcare applications.

Allozymes is a pioneering company specializing in advanced microfluidics technology. It accelerates enzyme evolution and development by creating sensitive assays for detecting enzymatic reactions, proprietary microfluidic chips, and proteomics technologies.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Artyc specializes in providing sustainable cold shipping solutions tailored for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers that enhance the efficiency of cold logistics. By focusing on decarbonizing the cold chain, Artyc aims to create a more sustainable logistics industry. Their innovative containers not only help businesses reduce shipping costs but also enable effective temperature monitoring, ensuring the safe transport of sensitive goods.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Bioeutectics develops and supplies high-performance, natural solvents for industrial processes. Utilizing eutectic technology and renewable resources, the company produces eco-friendly alternatives to petrochemical solvents, serving industries such as personal care, food ingredients, agro-tech, and green tech.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

Mazlite develops an industrial IoT platform for spray monitoring and digitization in hazardous environments. The system combines imaging hardware sensors with web-based software, real-time analytics powered by physics-based artificial intelligence, and cloud-based data management to help manufacturers monitor and optimize spray processes. The platform targets automotive paint and pharmaceutical manufacturing, enabling real-time spray monitoring, identification of product quality issues, improved sustainability, reduced material and energy waste, and fewer scraps and repairs.

Oxyle specializes in wastewater treatment, focusing on the removal of hazardous micropollutants such as pesticides, chemicals, pharmaceuticals, and endocrine disruptors. Serving industries like pharmaceuticals, biotech, chemicals, food & beverage, electronics, hospitals, and wastewater plants, Oxyle's innovative technology helps reduce toxic pollutants and carbon emissions while providing regulatory relief to clients.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Aima is a Vancouver-based company founded in 2019 that focuses on transforming the management of menstrual pain. The company provides a weekly proactive pain management system designed specifically for menstruators, offering personalized and effective solutions to address period pain. Aima's platform aims to empower users by enabling them to manage their pain with greater freedom and dignity. Through its innovative approach, Aima seeks to improve the overall experience of menstruators by providing accessible and tailored pain relief options.

Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

Bioeutectics develops and supplies high-performance, natural solvents for industrial processes. Utilizing eutectic technology and renewable resources, the company produces eco-friendly alternatives to petrochemical solvents, serving industries such as personal care, food ingredients, agro-tech, and green tech.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Artyc specializes in providing sustainable cold shipping solutions tailored for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers that enhance the efficiency of cold logistics. By focusing on decarbonizing the cold chain, Artyc aims to create a more sustainable logistics industry. Their innovative containers not only help businesses reduce shipping costs but also enable effective temperature monitoring, ensuring the safe transport of sensitive goods.

Artyc specializes in providing sustainable cold shipping solutions tailored for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers that enhance the efficiency of cold logistics. By focusing on decarbonizing the cold chain, Artyc aims to create a more sustainable logistics industry. Their innovative containers not only help businesses reduce shipping costs but also enable effective temperature monitoring, ensuring the safe transport of sensitive goods.

Founded in August 2019, Portable Diagnostic Systems develops a microfluidics-based drug testing platform for law enforcement. This platform uses salivary diagnostics, antibody engineering, and micro-fluidics to accurately screen drugs from a small saliva sample collected at roadside stops, aiming to reduce false positives and enhance traffic stop efficiency.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

RxAll, Inc. is a technology company that specializes in developing an artificial intelligence-driven platform for the authentication and distribution of pharmaceuticals, primarily in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) platform that incorporates a molecular sensor device and a cloud database of spectral signatures. This innovative approach allows for non-destructive authentication of medications, including prescription and over-the-counter drugs, before they are dispensed. RxAll aims to combat the issue of counterfeit drugs by providing real-time information to pharmaceutical manufacturers about the authenticity of their products. Additionally, the platform facilitates access to authenticated medicines for patients and pharmacies, while also offering tele-pharmacy primary care services.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Allozymes is a pioneering company specializing in advanced microfluidics technology. It accelerates enzyme evolution and development by creating sensitive assays for detecting enzymatic reactions, proprietary microfluidic chips, and proteomics technologies.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that modulate RNA targets linked to cancer and neurodegenerative diseases. The company uses a proprietary platform that combines high-throughput screening, computational modeling, and machine learning with unique datasets to discover RNA-targeting compounds with potency and selectivity for traditionally inaccessible targets. Its approach includes RNA biosensor technologies that render target molecules detectable, aiding discovery and evaluation. Founded in 2021 and based in Seattle, Wayfinder aims to accelerate development of therapies for undruggable targets by enabling rapid screening and optimization of RNA-targeting small molecules.

Allozymes is a pioneering company specializing in advanced microfluidics technology. It accelerates enzyme evolution and development by creating sensitive assays for detecting enzymatic reactions, proprietary microfluidic chips, and proteomics technologies.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

RxAll, Inc. is a technology company that specializes in developing an artificial intelligence-driven platform for the authentication and distribution of pharmaceuticals, primarily in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) platform that incorporates a molecular sensor device and a cloud database of spectral signatures. This innovative approach allows for non-destructive authentication of medications, including prescription and over-the-counter drugs, before they are dispensed. RxAll aims to combat the issue of counterfeit drugs by providing real-time information to pharmaceutical manufacturers about the authenticity of their products. Additionally, the platform facilitates access to authenticated medicines for patients and pharmacies, while also offering tele-pharmacy primary care services.

AsimicA, founded by Nikolai Mushnikov and Grant Bowman in November 2018, specializes in developing innovative technologies aimed at enhancing production efficiency in microbial biosynthetic factories. The company's core focus is on improving yields of biosynthetic processes, a significant challenge in biotechnology due to relatively low product outputs. AsimicA's novel approaches, centered around microbial stem cell technology, have the potential to revolutionize the industry by enabling multi-fold increases in production efficiency, particularly for pharmaceutical biomolecules.

Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

ANA Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic solutions for the treatment of coronavirus, specifically COVID-19. Founded in 2020 and based in Foster City, California, the company is advancing a proprietary formulation of niclosamide, marketed under the name ANA001. This drug is delivered in capsule form and is currently undergoing human clinical trials. The objective of ANA Therapeutics is to provide effective treatment options for medical practitioners to help patients affected by the coronavirus pandemic, thereby aiming to contribute to the global response to this public health crisis.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

ANA Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic solutions for the treatment of coronavirus, specifically COVID-19. Founded in 2020 and based in Foster City, California, the company is advancing a proprietary formulation of niclosamide, marketed under the name ANA001. This drug is delivered in capsule form and is currently undergoing human clinical trials. The objective of ANA Therapeutics is to provide effective treatment options for medical practitioners to help patients affected by the coronavirus pandemic, thereby aiming to contribute to the global response to this public health crisis.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

RxAll, Inc. is a technology company that specializes in developing an artificial intelligence-driven platform for the authentication and distribution of pharmaceuticals, primarily in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) platform that incorporates a molecular sensor device and a cloud database of spectral signatures. This innovative approach allows for non-destructive authentication of medications, including prescription and over-the-counter drugs, before they are dispensed. RxAll aims to combat the issue of counterfeit drugs by providing real-time information to pharmaceutical manufacturers about the authenticity of their products. Additionally, the platform facilitates access to authenticated medicines for patients and pharmacies, while also offering tele-pharmacy primary care services.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Allozymes is a pioneering company specializing in advanced microfluidics technology. It accelerates enzyme evolution and development by creating sensitive assays for detecting enzymatic reactions, proprietary microfluidic chips, and proteomics technologies.

Sothic Bioscience Ltd. is a biotechnology company based in Cork, Ireland, founded in 2015. The company focuses on developing a bio-production platform, LimuleX, which aims to create bio-identical replacements for naturally sourced limulus amebocyte lysate. This innovation seeks to eliminate the reliance on the threatened horseshoe crab species in the pharmaceutical quality control supply chain. Sothic Bioscience is currently engaged in the lab bench production phase of a highly specific pyrogen contamination testing reagent, which is crucial for pharmaceutical and medical device testing. To scale up production and bring its products to market, the company is in the process of raising seed capital. Through its innovative approach, Sothic Bioscience is committed to providing sustainable alternatives for high-value biomolecules used in various biomedical applications.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Hexafly is a biotech company based in Kells, Ireland, established in 2016. It specializes in the sustainable farming of insects, particularly the Black Soldier Fly larvae, to produce various products for the aquaculture, animal feed, and plant nutrition sectors. The company focuses on converting food waste into protein meals, oils, and fertilizers, promoting a circular economy. Its product range includes insect oil for fish feed, protein additives for aquaculture, Frass for plant nutrition, and Chitin, a versatile bio-polymer utilized in medicine, cosmetics, and food. Hexafly sells its products online, aiming to provide environmentally friendly solutions in agriculture and contribute to a sustainable food system.

Bioprocol is a company established in 2004 that specializes in producing natural materials derived from plants sourced ethically through the sustainable use of Colombian biodiversity. Utilizing scientifically validated methods, Bioprocol focuses on developing raw materials for the pharmaceutical, cosmetics, and nutraceutical industries. The company's offerings primarily serve the skincare sector, aiming to restore skin health and enhance beauty. By providing high-added value innovations, Bioprocol supports its customers in their pursuit of health, beauty, and overall well-being.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

CyCa OncoSolutions Pvt. Ltd. is a technology company focused on developing innovative molecular devices for the programmable delivery of anticancer drugs directly into cells. Established in 2017 and headquartered in Balasore, India, the company specializes in creating drug delivery systems that can effectively cross cellular membrane bilayers to introduce functional molecules, such as anticancer drugs, water-soluble dyes, and imaging agents, into the cytoplasm or other organelles. CyCa OncoSolutions aims to support pharmaceutical and biotechnology firms in enhancing the brand lifecycle of their drugs and therapeutic molecules through its advanced technology.

Founded in 2011, Dahlia Biosciences is a biotechnology company specializing in single-cell RNA analysis tools for research and diagnostic applications. It uses CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly in cells and tissues.

Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.

Serenity Bioworks is a biotechnology company focused on developing innovative antibody mimetics for targeted protein degradation. The company employs advanced display techniques alongside computational methods to optimize the discovery process of these therapeutics. Additionally, Serenity Bioworks is engaged in creating gene therapies aimed at addressing underserved areas in healthcare, such as hemophilia, inherited retinal diseases, and neurodegenerative conditions. Their goal is to enhance the long-term efficacy and safety profiles of gene therapy treatments, ultimately improving patient outcomes with safer and more durable solutions.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Biospin is an introducing a revolutionary microbial detection system that provides gold standard detection of pathogens for F&B, water, consumer goods and pharmaceutical products in real time.

Synthace is a software company that develops tools for life sciences R&D, enabling automation, digitization, and optimization of biological experiments across health, pharmaceutical, food, energy, and industrial biotechnology sectors. Its cloud-based Antha platform lets users visually design, execute, and analyze biological workflows and automates processes to improve success rates. The platform digitizes experiments end to end, allowing researchers to plan reproducible experiments, simulate them, run them on automation equipment, and automatically structure data and metadata in a centralized workspace. It enables codeless reprogramming of liquid handling and supports multifactorial experimentation by connecting experimental data with other digital tools in the ecosystem. The software is browser-based, requires no coding, and aims to streamline lab workflows, improve data quality, and broaden the scope of experiments that can be conducted. The company operates globally from its base in London, with additional presence in the United States.